

JUL 09 2004

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of:

Jamie L. Brewer, et al.

Serial No.: 10/612,121

Filed: July 2, 2003

Art Unit: 1645

Examiner: Unknown

Atty. Docket No.: 260385.20005

Customer No.: 026148

COMPOSITIONS AND METHOD FOR  
THE DETECTION OF HUMAN T CELL  
RECEPTOR VARIABLE FAMILY GENE  
EXPRESSION

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98. Enclosed is Form PTO-1449 which lists the references cited along with a copy of each of the references. Also enclosed is a copy of the European Search Report which corresponds to the subject US application.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this paper (along with any document referred to as being attached or enclosed) is being

**EXPRESS MAIL NO. EV 398 729 505 US**


**FACSIMILE**

☒ deposited with the United States Postal Service as Express Mail under 37 CFR 1.10 on July 7, 2004 addressed to the: Commissioner for Patents, Alexandria, VA 22313.

☐ transmitted by facsimile on [date] to the U.S. Patent and Trademark Office.

Ruth Montalvo

Type Signature Name

  
(Signature of person mailing paper or fee)

\_\_\_\_\_  
(Signature of person mailing paper or fee)

The references may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider each of these items and to independently ascertain their teaching.

1. ☒ Enclosed is PTO Form 1449 (and a duplicate thereof).
2. ☐ Items listed on the enclosed Form PTO-1449 are not in the English language.

☐ For each of the following items, an English-language translation of that item or a portion thereof or a concise explanation of the relevance of that item is attached.

☐ For each of the following items, a concise explanation of that item is incorporated in the specification of the above-identified application:

☐ For each of the following items, a corresponding U.S. or other English-language patent is enclosed. Please consider the U.S. or other English-language patents in accordance with the procedure set forth in MPEP § 609:

3. ☐ Submission in Accordance with 37 CFR § 1.98(d).

Any copy of the items listed on the enclosed Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in Application Serial No. [Ser. No.], filed [Date], of which the present application relies upon for an earlier filing date under 35 U.S.C. 120.

4. ☒ Submission in Accordance with 37 CFR § 1.97(b).

This Information Disclosure Statement is being filed

- ☐ With the application;
- ☐ Within three months of the filing date of a national application;
- ☐ Within three months of the date of entry of the national stage in an international application; or
- ☒ Before the mailing date of a first Office Action on the merits,

and NO FEE is due for consideration of this Information Disclosure Statement.

5. ☐ **Submission in Accordance with 37 CFR 1.97(c).**

This Information Disclosure Statement is being filed before the first mailing date of either

☐ A final action under § 1.113; or

☐ A notice of allowance under § 1.311.

☐ A fee is due for consideration of this Information Disclosure Statement and the fee is paid below; or

☐ This Information Disclosure Statement is accompanied by one of the certifications pursuant to 37 CFR § 1.97(e), and NO FEE is due for consideration of this Information Disclosure Statement.

6. ☐ **Submission in Accordance with 37 CFR 1.97(d).**

This Information Disclosure Statement is being filed after the mailing date of either

☐ A final action under § 1.113; or

☐ A notice of allowance under § 1.311,

whichever comes first, but before payment of the issue fee, and is accompanied by

a. One of the certifications pursuant to 37 CFR § 1.97(e), which is set forth below;

b. The attached petition requesting consideration of this Information Disclosure Statement; and

c. The petition fee under 37 CFR § 1.17(i)(1), which is paid below.

7. **Certification Pursuant to 37 CFR 1.97(e).**

☐ The undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application not more than three months prior to the filing of this Information Disclosure Statement; or


☐ The undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign

application, or to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

8. Fee Payment Being Made.


- ☐ Enclosed
- ☐ \$240.00 fee for submission under 37 CFR § 1.97(c).
- ☐ \$130.00 fee for submission under 37 CFR § 1.97(d).
- ☐ A check in the amount of \$[Amount] to cover the fee payment is enclosed.
- ☐ Charge the fee to Deposit Account No. 50-1529. A duplicate copy of this communication is attached.
- ☒ The Director is hereby authorized to charge payment of any additional fees associated with this Information Disclosure Statement or credit any overpayment to Deposit Account No. 50-1529. A duplicate copy of this communication is enclosed.

Respectfully submitted,



Eugene Ledonne  
Reg. No. 35,930  
REED SMITH LLP  
599 Lexington Avenue  
29<sup>th</sup> Floor  
New York, NY 10022  
Telephone No. 212-521-5400

Attorney for Applicants



PTO/SB/08b(05-03)

Approved for use through 05/31/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/612,121		
		Filing Date	July 2, 2003		
		First Named Inventor	Jami Brewer, et al.		
		Art Unit	1645		
		Examiner Name	Unknown		
Sheet	1	of	1	Attorney Docket Number	260385.20005

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		GENEVÉE, C., et al., "An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction", Dur. J. Immunol., May 1992, Vol. 22, pages 1261-1269.	✓
		ROMAN-ROMAN, S., et al., "Studies on the human T cell receptor alpha/beta variable region genes, I. Identification of seven additional V alpha subfamilies and fourteen J alpha gene segments. Eur. J. Immunol., April 1991, Vol. 21, pages 927-933.	✓
		SPINELLA, D.G., et al., "Analysis of Human T-Cell Repertoires by PCR." in The Polymerase Chain Reaction, (Birkhauser, MULLIS, K.B., ed.), 1994, pages 110-120.	✓

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.